SGMO News and Press, Sangamo Therapeutics Inc. From 09/04/25

Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care STAAR study demonstrated positive mean annualized estimated...

2025-08-08 14:53:54 ET Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Conference Call August 07 2025, 04:30 PM ET Company Participants Alexander D. Macrae - CEO, President & Director Gregory Davis - Head of Research & Technology Louise Wilkie - Head o...

2025-08-07 16:04:52 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript Sangamo Therapeutics, Inc. 2025 Q1 - Results - Earnings Call Presentation Sangamo Therapeutics Q2 2025 Earnings Preview Sangamo rises after ...

Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as prim...

Leatt Corp (LEAT) is expected to report for Q2 2025 MDU Resources Group Inc. (Holding Company) (MDU) is expected to report $0.13 for Q2 2025 Video Display Corp. (VIDE) is expected to report for quarter end 2025-05-31 Alarm.com Holdings Inc. (ALRM) is expected to report $0.38 for Q2 20...

Sangamo Therapeutics Inc. (SGMO) is expected to report $-0.07 for Q2 2025

RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on Thursday, August 7, 2025. The company wi...

2025-06-24 08:46:36 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript Sangamo Therapeutics, Inc. 2025 Q1 - Results - Earnings Call Presentation Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing...

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval Isaralgagene civaparvovec showed a favor...

2025-05-13 04:36:16 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript Sangamo Therapeutics, Inc. 2025 Q1 - Results - Earnings Call Presentation Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing...